Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cluster immunotherapy - Inmunotek/ROXALL Medizin GmbH

Next Previous
Drug Profile

Cluster immunotherapy - Inmunotek/ROXALL Medizin GmbH

Alternative Names: Alxoid; CLU-RX-DPT - ROXALL Medizin GmbH; CLU-RX-PHL; Clustek; Cluster-allergoid - ROXALL Medizin GmbH; CLUSTOID; CLUSTOID® Wiesenlieschgras; CLUSTOID® Timothy; CLUSTOID® Phleum pretense; DERMATOPHAGOIDES PTERONYSSINUS ALLERGOID - ROXALL Medizin GmbH; Glutaraldehyde polymerised allergen extract - ROXALL Medizin GmbH; GLUTARALDEHYDE-MODIFIED - ROXALL Medizin GmbH; Roxoid

Latest Information Update: 07 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inmunotek
  • Developer Inmunotek; ROXALL Medizin GmbH
  • Class Allergens; Allergy immunotherapies; Antiallergics; Vaccines
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic rhinitis
  • Phase II/III Rhinoconjunctivitis

Most Recent Events

  • 18 Aug 2025 Phase-II/III clinical trials in Allergic rhinitis (In adults) in Germany, Kazakhstan, Turkey, Ukraine (SC) (CTIS2024-517521-25-00)
  • 18 Aug 2025 Phase-II/III clinical trials in Rhinoconjunctivitis (In adults) in Ukraine, Germany, Turkey, Kazakhstan (SC) (CTIS2024-517521-25-00)
  • 11 Jun 2025 ROXALL Medizin GmbH initiates a phase II/III trial in Rhinoconjunctivitis in Germany (SC) (CTIS2024-517014-15-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top